Stock TENX TENAX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tenax Therapeutics, Inc.

Equities

TENX

US88032L6056

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
3.48 USD -3.33% Intraday chart for Tenax Therapeutics, Inc. -4.13% -84.16%
Mar. 28 Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 28 Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 9.505 23.47 26.21 4.979 6.553 6.815 - -
Enterprise Value (EV) 1 9.505 23.47 26.21 4.979 6.553 6.815 6.815 6.815
P/E ratio -1.04 x -1.4 x -0.66 x -0.3 x -0.71 x -0.47 x -0.96 x -1.29 x
Yield - - - - - - - -
Capitalization / Revenue - - - - - - - 1.64 x
EV / Revenue - - - - - - - 1.64 x
EV / EBITDA - -2,379,569 x - - - - - -
EV / FCF -1,257,254 x -2,530,275 x - - - - - -
FCF Yield -0% -0% - - - - - -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 4.21 7.89 15.8 27.9 298 1,958 - -
Reference price 2 2,256 2,976 1,664 178.2 21.97 3.480 3.480 3.480
Announcement Date 3/30/20 3/31/21 3/29/22 3/31/23 3/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - - 4.156
EBITDA - -9.864 - - - - - -
EBIT 1 -8.555 -9.868 -32.73 -11.05 -8.234 -16.24 -18.4 -16.02
Operating Margin - - - - - - - -385.48%
Earnings before Tax (EBT) 1 -8.394 -9.851 -32.47 -11.05 -7.711 -16.24 -18.4 -16.02
Net income 1 -8.394 -9.851 -32.47 -11.05 -7.711 -16.24 -18.4 -16.02
Net margin - - - - - - - -385.48%
EPS 2 -2,160 -2,128 -2,528 -600.8 -31.04 -7.425 -3.630 -2.695
Free Cash Flow -7.56 -9.276 - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/30/20 3/31/21 3/29/22 3/31/23 3/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - - - -
EBITDA - - - - - - - - - - - - - -
EBIT 1 -3.802 -3.212 - -2.862 -2.917 -2.555 -1.539 -1.236 -2.117 -3.341 -3.507 -3.23 -3.644 -3.956
Operating Margin - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -3.799 -3.211 - -2.861 -2.917 -2.549 -1.407 -1.106 -1.972 -3.226 -3.507 -3.23 -3.644 -3.956
Net income 1 -3.799 -3.211 -2.722 -2.861 -2.917 -2.549 -1.407 -1.106 -1.972 -3.226 -3.507 -3.23 -3.644 -3.956
Net margin - - - - - - - - - - - - - -
EPS 2 -240.0 -64.00 -176.0 -176.0 -176.0 -72.80 -12.00 -4.000 -6.400 -8.640 -2.400 -1.645 -1.770 -1.185
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/15/21 3/29/22 5/16/22 8/11/22 11/10/22 3/31/23 5/15/23 8/14/23 11/13/23 3/28/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow -7.56 -9.28 - - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 0 - - - - - - -
Capex / Sales - - - - - - - -
Announcement Date 3/30/20 3/31/21 3/29/22 3/31/23 3/28/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.48 USD
Average target price
32.5 USD
Spread / Average Target
+833.91%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TENAX THERAPEUTICS, INC. Stock Tenax Therapeutics, Inc.
-84.16% 6.81M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TENX Stock
  4. Financials Tenax Therapeutics, Inc.